Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors

Vaccine

Volumn 30, Issue 7, 2012, Pages 1313-1321

  Fang, Xinkui ^a,b   Zhang, Shikuan ^c   Sun, Xiaodong ^a   Li, Jinjin ^a   Sun, Tao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Municipal Veterinary Key laboratory   (China)

^c NANCHANG UNIVERSITY   (China)

Author keywords

Glycoprotein; Matrix protein; Vaccine vector; Vesicular stomatitis virus

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; M PROTEIN; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CRICETINAE; FEMALE; IMMUNITY, ACTIVE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; SEQUENCE DELETION; VACCINATION; VACCINES, ATTENUATED; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 84856575570     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.085     Document Type: Article

References (29)

1. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 1995, 92(10):4477-4481.
2. Whelan S.P., Ball L.A., Barr J.N., Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 1995, 92(18):8388-8392.
3. Schnell M.J., Buonocore L., Kretzschmar E., Johnson E., Rose J.K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996, 93(21):11359-11365.
4. Martinez I., Barrera J.C., Rodriguez L.L., Wertz G.W. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. Vaccine 2004, 22(29-30):4035-4043.
5. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Möller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78(10):5458-5465.
6. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005, 86(5):1435-1440.
7. Majid A.M., Ezelle H., Shah S., Barber G.N. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol 2006, 80(14):6993-7008.
8. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., L.Buonocore, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998, 72(6):4704-4711.
9. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106(5):539-549.
10. Bi Z., Barna M., Komatsu T., Reiss C.S. Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 1995, 69(10):6466-6472.
11. Johnson J.E., Nasar F., Coleman J.W., Price R.E., Javadian A., Draper K., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360(1):36-49.
12. Rose J.K., Whitt M.A. Rhabdoviridae: the viruses and their replication. Fields Virology 2001, 1221-1244. Lipopincot Willianms & Wilkins, Philadelphia. vol. 1.
13. Kopecky S.A., Lyles D.S. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 2003, 77(9):5524-5528.
14. Martinez I., Rodriguez L.L., Jimenez C., Pauszek S.J., Wertz G.W. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 2003, 77(14):8039-8047.
15. Harty R.N., Paragas J., Sudol M., Palese P. A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol 1999, 73(4):2921-2929.
16. Irie T., Carnero E., Okumura A., García-Sastre A., Harty R.N. Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo. J Gen Virol 2007, 88(9):2559-2567.
17. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4(4):263-275.
18. Whitt M.A., Chong L., Rose J.K. Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant. J Virol 1989, 63(9):3569-3578.
19. Schnell M.J., Buonocore L., Boritz E., Ghosh H.P., Chernish R., Rose J.K. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J 1998, 17(5):1289-1296.
20. OWENS1 Randall J., Rose John K. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular Stomatitis virus. J Virol 1993, 67(1):360-365.
21. Ebert O., Harbaran S., Shinozaki K., Woo S.L. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2005, 12(4):350-358.
22. Roberts A., Buonocore L., Price R., Forman J., Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999, 73(5):3723-3732.
23. Hayman A., Comely S., Lackenby A., Hartgroves L.C., Goodbourn S., McCauley J.W., et al. NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta nterferon response. J Virol 2007, 81(5):2318-2327.
24. Diaz M.O., Ziemin S., Le Beau M.M., Pitha P., Smith S.D., Chilcote R.R., et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 1988, 85(14):5259-5263.
25. García-Sastre A., Egorov A., Matassov D., Brandt S., Levy D.E., Durbin J.E., et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252(2):324-330.
26. Flanagan E.B., Zamparo J.M., Ball L.A., Rodriguez L.L., Wertz G.W. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 2001, 75(13):6107-6114.
27. Ahmed M., Cramer S.D., Lyles D.S. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004, 330(1):34-49.
28. Lun X., Senger D.L., Alain T., Oprea A., Parato K., Stojdl D., et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 2006, 98(21):1546-1557.
29. Critchley-Thorne R.J., Simons D.L., Yan N., Miyahira A.K., Dirbas F.M., Johnson D.L., et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 2009, 106(22):9010-9015.